鹿児島大学 · 医歯学域附属病院

研究キーワードadult T-cell leukemia and lymphoma・HTLV-1-associated malignancy・arsenic trioxide apoptosis・PD-1 and PD-L1 Expression・gamma-secretase inhibition・lymphomatoid granulomatosis・hematologic neoplasms・IDH-mutant astrocytoma

ここは公開データのプレビューです。個別の適合理由、連絡角度、保存機能はログイン後に利用できます。

• Kirishima M., Akahane T., Higa N., Suzuki S., Ueno S., Yonezawa H., Uchida H., Hanaya R., Yoshimoto K., Shimajiri S., Kitazono I., Tanimoto A. . IDH-mutant astrocytoma with an evolutional prog2022 · 記述言語： 日本語 出版者・発行元： Pathology Research and Practice We reported a case of molecularly defined isocitrate dehydrogenase (IDH)-mutant astrocytoma that recurred twice with aggressive behavior and increased anaplastic morphology. Primary and recurrent tumors were analyzed using custom-made DNA-based cancer gene and RNA-based fusion panels for next-generation sequencing (NGS). NGS analyses revealed that recurrent astrocytoma, in addition to IDH1 and tumor protein 53 mutations detected in the primary lesion, harbored cyclin-dependent kinase inhibitor (CDKN) 2 A/B homozygous deletion and neurotrophic tropomyosin receptor kinase 2 (NTRK2) fusion genes that consisted of golgin A1- and cyclin-dependent kinase 5 regulatory subunit associated protein 2-NTRK2 fusions. Anaplasia and necrosis were observed in the recurrent tumors, but not in the primary lesion. Therefore, the integrative diagnosis was primary IDH-mutant astrocytoma grade 2 and recurrent IDH-mutant astrocytoma grade 4 with NTRK2 fusions. This is a worthwhile report describing a case of IDH-mutant astrocytoma that showed genomic evolution during tumor recurrence. Our report suggests that NTRK fusion and CDKN2A/B homozygous deletion promote high-grade transformation and indicate an unfavorable prognosis of IDH-mutant astrocytoma. DOI： 10.1016/j.prp.2022.154163 Scopus PubMed
• Kawada H, Yoshimitsu M, Nakamura D, Arai A, Hayashida M, Kamada Y, Maekawa K, Fujino S, Arima M, Arima N, Tabuchi T, Inoue H, Hamda H, Suzuki S, Matsushita K, Arima N.2015 · 記述言語： 英語 掲載種別： 研究論文（学術雑誌）
• Kawahira M., Kanmura S., Mizuno K., Machida K., Ohtsuka T., Sato M., Enokida H., Yamashita M., Kanekura T., Arima S., Nakamura N., Sugiura T., Yoshimoto K., Kobayashi H., Ishitsuka K., Suzuki S., Ueno2014 · 記述言語： 日本語 出版者・発行元： PLoS ONE Background and aims Immune checkpoint inhibitors (ICIs) are used to treat several cancers, but they sometimes induce immune-related adverse events (irAEs). Patients with irAEs often have improved antitumor responses, but discontinuation of ICIs after irAEs is considered necessary. Resuming the use of ICIs after irAEs is preferable, but few studies have investigated the safety of ICI resumption after irAEs. Therefore, we evaluated the factors associated with the recurrence of irAEs after ICI resumption to investigate the safety of this approach. Methods In this observational study, we enrolled patients treated with ICIs from September 2014 to March 2020 at our institution. Patient characteristics, ICIs, grades of irAEs, ICI discontinuation or resumption rates, and recurrence rates of irAEs after ICI therapy were analysed. Results Two-hundred eighty-seven patients were included in the present study, and 76 patients experienced grade 2 or higher irAEs. Forty-two patients underwent ICI resumption after recovering from irAEs, and 13 of them had a recurrence of irAEs. Among those 13 patients, six had a recurrence of the same irAE, and seven experienced other irAEs. Ten of the 13 patients had grade ≥2 irAEs, and none had fatal irAEs. In the grade 2 or higher irAE group, more patients had irAEs associated with multiple organs and of initial grade ≥2 than those in the grade 1 and no recurrent irAEs group. Conclusions Patients with initial multisystemic irAEs and irAEs of grade ≥2 were more likely to experience relapse or develop new grade ≥2 irAEs after ICI resumption. DOI： 10.1371/journal.pone.0267572 Scopus PubMed
• White Y, Yoshimitsu M, Kozako T, Matsushita K, Koriyama C, Uozumi K, Suzuki S, Kofune H, Arima N.2013 · 記述言語： 英語 掲載種別： 研究論文（学術雑誌）

• 生体内ゲノム編集を利用したHTLV-1を標的にする新規抗ウイルス療法2019 · 2019年4月 - 現在
• 発がんウィルスであるHTLV-1を標的にした遺伝子組み替えウィルス療法2015 · 2015年4月 - 2017年3月
• 成人Ｔ細胞白血病幹細胞の遺伝子治療2011 · 2011年4月 - 2013年3月
• 白血病幹細胞を標的とした成人T細胞白血病の新規化学療法の開発2010 · 2010年4月 - 2012年3月

• 公式プロフィール